Introduction
============

Dendritic spines compartmentalize biochemical cascades at the postsynaptic level and are enriched in neurotransmitter receptors, ion channels, and components of various signaling pathways ([@B11]; [@B17]), including the Wnt signaling pathway ([@B29]; [@B6]).

The signaling pathways mediated through Wnt have been implicated in various cellular processes, including cell proliferation, migration, establishment of polarity, cell fate specification, and adult hippocampal neurogenesis ([@B43]; [@B49]; [@B63]). Therefore, deregulation of Wnt signaling has been associated with the development of several diseases, including autism ([@B70]; [@B58]), schizophrenia ([@B45]; [@B30]), and Alzheimer disease (AD; [@B31]; [@B51]; [@B32]). Recently, a number of studies have highlighted a role for Wnt signaling in synaptic formation and function ([@B23]; [@B13]; [@B47]). In particular, we showed that the Wnt-5a ligand exerts important effects in the postsynaptic region of hippocampal neurons. For example, Wnt-5a stimulation increases the: GABAa receptor recycling ([@B19]), the clustering of postsynaptic density (PSD) protein 95 (PSD-95; [@B22]) and the density of dendritic spines ([@B61]). Moreover, in hippocampal slices, Wnt-5a modulates synaptic activity through the enhancement of long-term potentiation (LTP; [@B9]; [@B65]). These findings indicate that Wnt-5a regulates the assembly and function of the excitatory postsynaptic region of central synapses ([@B32]). However, the mechanism underlying these effects is still elusive.

Recently, we explore a new mechanism of regulation mediated by Wnt-5a that includes the modulation of microRNAs (miRNAs). MiRNAs are a family of small non-coding RNAs, that control the gene expression of their targets through base pairing between the 3′ untranslated region (UTR) of mRNA and miRNA "*seed"* region at the 5′ end, thereby inhibiting the translation of the target proteins ([@B4]). We identified more than 30 miRNAs with differential expression after 1 h treatment with Wnt-5a in cultured rat hippocampal neurons and miR-101b was the most affected miRNA after Wnt-5a signaling activation ([@B16]). While the role of miR-101b has been thoroughly investigated in cancerogenesis ([@B59]; [@B25]; [@B27]), the role for this miRNAs in the brain has just begun to emerge. It was reported that miR-101b regulates the expression of the amyloid precursor protein (APP; [@B66]; [@B44]; [@B3]), ataxin1 ([@B41]), and the Fragile X Mental Retardation gene 1 (FMR1; [@B72]) in the hippocampus.

Among the many targets predicted for miR-101b, we focused on SynGAP (Synaptic GTPase-Activating Protein), because it is an abundant key PSD signaling enzyme. It negatively regulates small G protein signaling downstream of glutamate receptor activation and is related to the regulation of synapse density, dendritic spine shape, and synaptic physiology ([@B46]). Conversely, alterations in SynGAP functions has been linked to intellectual disability (ID) and autism spectrum disorders (ASDs) ([@B5]). Additionally, several reports suggest that the upstream activator of SynGAP is Ca^2+^/calmodulin-dependent protein kinase II (CaMKII) which in turn is activated by increased calcium levels mediated by *N*-methyl-[D]{.smallcaps}-aspartic acid receptors (NMDAR) activation ([@B39]; [@B53]; [@B2]). Since Wnt-5a is able to down-regulate a miRNA that targets SynGAP *in silico* and activates the Wnt/Ca^2+^ signaling pathway in the dendritic compartments of mature hippocampal neurons ([@B61]), we evaluate whether SynGAP is part of the mechanism by which Wnt-5a induces changes at the post-synaptic region. Considering the neuroprotective effects of this ligand against amyloid-β oligomers (Aβ oligomers; [@B8]; [@B64]), we explore the effects of Wnt-5a over SynGAP, in the presence of Aβ oligomers.

Materials and Methods {#s1}
=====================

Ethics Statement
----------------

Sprague--Dawley rats were housed in the University Animal Facility and handled according to the guidelines outlined and approved through the Institutional Animal Care and Use Committee at the Faculty of Biological Sciences of the Pontificia Universidad Católica de Chile, and following the guidelines of the American Physiological Society Rockville, MD.

Primary Culture of Rat Hippocampal Neurons
------------------------------------------

Rat hippocampal cultures were prepared as previously described ([@B1]; [@B33]). Primary hippocampal neurons were obtained from 18-days-old Sprague--Dawley rat embryos and maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% horse serum for 2 h. The culture medium was subsequently substituted with Neurobasal medium supplemented with B27, 100 μg/ml streptomycin, and 100 units/ml penicillin. At 3 days *in vitro* (DIV), the cells were treated with 2 μM araC for 24 h to reduce the number of glial cells present in the culture. For western blot (WB) analyses, 400,000 cells per well were seeded, and for immunofluorescence studies, 35,000 cells were plated per well. At 14 DIV, the neurons were stimulated with 300 ng/mL of recombinant Wnt-5a (rWnt-5a; R&D System, Minneapolis, MN, USA) resuspended in Neurobasal medium. Incubations were conducted at 37°C.

HT22 Cell Line
--------------

HT22 murine hippocampal neuronal cells were maintained in DMEM supplemented with 10% fetal bovine serum, 100 μg/ml streptomycin, and 100 units/ml penicillin, high glucose and incubated at 37°C under 5% CO~2~ as previously described ([@B12]). Transfections were performed after 2 days at approximately 60% confluency.

Bioinformatics
--------------

For computational prediction of the miRNA targets, we used the TargetScan web platform ([@B42]), which predicts biological targets of miRNAs by searching for the presence of conserved 8- and 7-mer sites that match the seed region of each miRNA. In addition, TargetScan examines the binding sites for thermodynamic stability using RNAfold from the Vienna RNA Package ([@B24]).

miR-101b Gain-of-Function
-------------------------

For miR-101b gain-of-function, we used mirVana miRNA mimic (Life Technologies, Carlsbad, CA, USA), which represents a partially double-stranded RNA that mimics endogenous precursor miRNA and is processed to form an active miRNA molecule that targets specific mRNAs ([@B48]). For miR-101b gain-of-function in HT-22 cells, Lipofectamine 2000 reagent (Invitrogen, Karlsruhe, Germany) was used according to the manufacturer's protocol. At 48 h post-transfection, the cells were used for WB analysis. For controls conditions HT-22 cells were transfected with mirVana miRNA Mimic Negative Control \#1 (Life Technologies, Carlsbad) which correspond to a random sequence miRNA mimic molecule that not produce identifiable effects on known miRNA function.

Western Blot Analysis
---------------------

The extraction of total protein from cell culture of hippocampal neurons and immunoblot analysis were performed as previously described ([@B62]; [@B15]). The following primary antibodies were used: rabbit anti-pSynGAP (1:1.000; ABCAM), rabbit anti-SynGAP (1:1.000; ABCAM), mouse anti pCAMKII (1:1.000, Santa Cruz), and anti GAPDH (1:10.000, Santa Cruz). Primary antibodies were recognized using either a horseradish peroxidase (HRP)-conjugated goat anti-rabbit antibody (1:7000, Thermo Scientific) or an HRP-conjugated rabbit anti-mouse antibody (1:7.000 Thermo Scientific). The secondary antibodies were detected through enhanced chemiluminescence using the ECL Plus Western blotting detection system (GE Healthcare). Densitometric analysis was performed using NIH ImageJ software.

Immunofluorescence and Microscopy
---------------------------------

Immunofluorescence studies were performed as previously described ([@B62]; [@B15]). Briefly, 14--16 DIV hippocampal neurons were depleted with Neurobasal medium (Invitrogen Corporation, Carlsbad, CA, USA) 1 h before treatment. Then, cells were treated *in vitro* with 300 ng/mL rWnt-5a and/or 1 μM Aβ1-42 oligomers following a time curve (0, 15, 30, 60, and 120 min). In every case, cells were kept at 37°C in incubator with 95% O~2~. Following treatment, cells were washed three times with PBS Ca^2+/^Mg^2+^ and fixated with paraformaldehyde 4%--sucrose 4%. After another round of washes, cells were permeabilized with PBS Ca^2+/^Mg^2+^ + Triton X 0.2%. Then, cells were immunolabeled with anti-SynGAP antibody (1:500, ABCAM) overnight at 4°C. On the next day, cells where washed as previously stated, and incubated with Alexa-conjugated secondary antibodies for 30 min at 37°C and Höescht staining (1:1000) for 10 min at room temperature. Coverslips were mounted using Fluoromont G mounting media and analyzed on an Olympus Takyo Japan Fluoview FV 1000 confocal microscope.

Aβ~1-42~ Oligomers Preparation
------------------------------

A lyophilized stock peptide was resuspended in anhydrous sterile dimethyl sulfoxide (DMSO), to form 5 mM aliquots that were immediately frozen. Aliquotes were diluted in PBS, pH 7.4 to a final concentration of 100 μM and stirred continuously approximately at 1350 rpm for 1 h at room temperature. Final concentrations for immunofluorescence studies were 5 μM Aβ oligomers and 0.02% DMSO. Control of the monomers to tetramers oligomeric (low molecular weight) species present after following this protocol can be found in previous publications from our group ([@B55]).

Statistical Analysis
--------------------

All data were analyzed statistically with Prism 5 (Prism GraphPad Software, GraphPad Software Inc., La Jolla, CA, USA) using one-way ANOVA, followed by Dunn's Multiple Comparison Test. The error bars indicate SEM. A *p* \< 0.05 was considered statistically significant.

Results
=======

SynGAP is a Target of miR-101b, a Wnt-5a-Regulated microRNA
-----------------------------------------------------------

The miRNAs recognition element for miR-101b in the 3′UTR of SynGAP (**Figure [1A](#F1){ref-type="fig"}**) corresponds to a canonical binding site (8-mer; **Figure [1B](#F1){ref-type="fig"}**) broadly conserved among mammals (**Figure [1C](#F1){ref-type="fig"}**). To validate the *in silico* prediction of SynGAP as a target of miR-101b, we introduced a miRNA mimic into the immortalized mouse hippocampal cell line, HT22, and evaluated the expression of endogenous SynGAP through WB. It is evident that the increase of miR-101b decreases the level of SynGAP in a dose-dependent manner (**Figures [1D,E](#F1){ref-type="fig"}**). This result validates the *in silico* prediction of SynGAP as a target of miR-101b and suggests that SynGAP expression could be modulated through Wnt-5a signaling via miR-101b. Considering that Wnt-5a signaling generates a significant decrease in the levels of miR-101b ([@B16]), we reasoned that the levels of SynGAP could be increased in the presence of Wnt-5a. Using WB analyses, we determined that treatment with recombinant protein Wnt5a (rWnt-5a) increases the levels of SynGAP in a time-dependent manner in primary hippocampal neurons (**Figures [1F,G](#F1){ref-type="fig"}**) which could be due to the loss of translational repression exercised by miR-101b.

![**Synaptic GTPase-Activating Protein (SynGAP) is a target of miR-101b, a Wnt-5a-regulated microRNA. (A)** Predicted binding site for the seed sequence of miR-101b in the 3′UTR of SynGAP. Obtained from TargetScan. **(B)** Complementarity of the sequences between miR-101b and the SynGAP 3′-UTR of rat genome obtained from TargetScan. **(C)** Degree of conservation in mammalian species obtained from TargetScan. **(D)** Endogenous levels of SynGAP are significantly decreased through gain-of function of miR-101b mimics in HT22 cells. **(E)** Densitometric analysis of the western blot (WB) shown in **(D)**. **(F)** WB analysis of total SynGAP levels in hippocampal neurons treated with recombinant Wnt-5a (300 ng/mL) at different time points. **(G)** Densitometric analysis of the WB experiments shown in **(F)**. The results are presented as the mean of *n* = 3 experiments, and the statistical analysis was performed using one-way ANOVA, followed by Dunn's Multiple Comparison Test ^∗^*p* \< 0.05.](fncel-09-00227-g001){#F1}

Wnt-5a Rapidly Increases the Phosphorylation Levels of SynGAP, Modulating SynGAP Clusters
-----------------------------------------------------------------------------------------

Synaptic GTPase-Activating Protein is a synaptic GTPase activating protein (GAP) that facilitates the hydrolysis of GTP to GDP and thereby negatively regulates the activity of RAS and RAP ([@B67]). The GAP activity of SynGAP is increased by direct phosphorylation of serine residues by CaMKII ([@B50]), another prominent component of the PSD. Since Wnt-5a is able to increase calcium levels at dendritic compartments, activates CaMKII and has a significant role in the organization of the PSD ([@B22]). We evaluated whether Wnt-5a is able to activate SynGAP. The treatment with recombinant Wnt-5a generates a fast and transient increase in the phosphorylation levels of S1123 of SynGAP (**Figures [2A,B](#F2){ref-type="fig"}**), a major phosphorylation site for CaMKII ([@B50]). Additionally, the kinetics of this activation is similar to the activation of CaMKII after Wnt-5a treatment (**Figures [2A,C](#F2){ref-type="fig"}**).

![**Wnt-5a increases the phosphorylation levels of SynGAP by a mechanism dependent of CamKII. (A)** WB analysis of pSynGAP (S1123) and p-calmodulin-dependent protein kinase II (CaMKII) levels in hippocampal neurons treated with recombinant Wnt-5a (300 ng/mL) at different time points. **(B)** Densitometric analysis of pSynGAP1, shown in **(A)**. **(C)** Densitometric analysis of pCaMKII, shown in **(A)**. The results are presented as the mean of *n* = 3 experiments and were normalized to GAPDH expression. **(D)** Representative neurite images of SynGAP immunofluorescence (green) from samples subjected to rWnt-5a (300 ng/mL) treatment for different time points, white bar represents 5 μm. **(E)** Quantification of the cluster density of SynGAP (cluster number/μm) in neurons described in **(A)**. **(F)** Model of the effect of Wnt-5a on SynGAP function. After binding of Wnt-5a to their receptors, there is an increase of intracellular calcium which could be due to a release from internal stores (Wnt/Ca^+2^ pathway) or modulation of NMDAR. Activation of CaMKII induces the increase in phosphorylation levels of SynGAP at S1123 and migration from dendritic clusters to a diffuse pool in the dendritic shaft. Statistical analysis was performed using one-way ANOVA, followed by Dunn's Multiple Comparison Test. ^∗^*p* \< 0.05.](fncel-09-00227-g002){#F2}

Synaptic GTPase-Activating Protein is expressed only in neurons, including most excitatory neurons and a subset of inhibitory neurons ([@B69]), where it is highly localized to the PSD ([@B10]). To evaluate the effects of Wnt-5a over the localization of SynGAP, we perform immunofluorescence studies on 14 DIV neurons treated with Wnt-5a at different time points.

Under control conditions, SynGAP showed a clear punctate localization (clusters) at dendrites which is consistent with previous studies on SynGAP's enrichment in dendritic spines ([@B37]). Interestingly, upon Wnt-5a treatment, the amount of SynGAP clusters was significantly reduced (**Figures [2D,E](#F2){ref-type="fig"}**). This reduction occurred within 15--30 min after Wnt-5a treatment and was not fully recovered after 1 h of stimulation (**Figures [2D,E](#F2){ref-type="fig"}**). The reduction in SynGAP clusters, as shown above, was not due to decreased levels of total protein as demonstrated by WB analysis (**Figures [1F,G](#F1){ref-type="fig"}**). This suggests that the reduction in the SynGAP cluster number is due to a translocation from dendritic spines to a diffuse pool in the shaft of the dendrite.

As shown in the model (**Figure [2F](#F2){ref-type="fig"}**), SynGAP is tightly associated with the postsynaptic plasma membrane and binds to the PDZ domains of PSD-95 ([@B37]) which positions it in close proximity to the NMDA receptors. Previous reports show that SynGAP is rapidly dispersed from spines upon NMDAR activation ([@B2]). This dispersion is mediated by direct phosphorylation by CaMKII. In our hypothetical model, the activation of CaMKII mediated by Wnt-5a should be able to induce a reduction in the clusters of SynGAP in hippocampal neurons. This is probably the result of the translocation of SynGAP from relatively large clusters in spines, to a diffuse pool in the dendritic shaft.

SynGAP Loss Induced by Aβ Oligomers is Prevented by Wnt-5a
----------------------------------------------------------

In the amyloid cascade hypothesis of AD, Aβ neurotoxicity has its origin in the binding of Aβ oligomers to the post-synaptic region ([@B26]). Aβ directly affects synaptic components including PSD-95 ([@B52]; [@B8]), NMDA receptors ([@B57]), and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs; [@B28]), to name a few ([@B21]). Still, there is no evidence of an effect of Aβ oligomers on SynGAP function. To evaluate this possibility we treated neurons with 5 μM Aβ oligomers at different time points. At this concentration, Aβ oligomers do not induce significant neuronal cell death; in the time frame we performed the experiments, as revealed by Höechst staining (Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}). This is in agreement with the idea that Aβ oligomers causes synaptic failure before neuronal death occurs ([@B26]). Aβ oligomers treatment generates a fast and important decrease in SynGAP clusters per μm of dendrite, this effect seems to be permanent in time (**Figure [3A](#F3){ref-type="fig"}**). By WB analysis we evaluate the effect of Aβ oligomers on the SynGAP levels. The treatment with Aβ generates a significant decrease in the total amount of SynGAP (**Figure [3C](#F3){ref-type="fig"}**) which is consistent with the decrease in the dendritic clusters of SynGAP and the previously reported synaptic loss induced by Aβ oligomers ([@B20]).

![**SynGAP loss induced by Aβ oligomers is rescued by Wnt-5a. (A)** Representative neurite images of SynGAP immunofluorescence (green) from samples subjected to a Aβ oligomers (5 μM) treatment for different time points, white bar represents 5 μm. Below, quantification of SynGAP (cluster number/μm) after Aβ oligomers treatment, compared to control condition, as seen in **(A)**. Significant differences are found at 15, 30, and 60 min. **(B)** Representative neurite images of SynGAP immunofluorescence (green) from samples subjected a co-application of rWnt-5a (300 ng/mL) plus Aβ oligomers (5 μM) treatment for different time points, white bar represents 5 μm. Below, quantification of SynGAP (cluster number/μm) after Aβ oligomers plus rWnt-5a treatment, compared to control condition, as seen in **(B)**. Significant differences are found only at 15 min. **(C)** WB analysis of total SynGAP levels in hippocampal neurons treated with Aβ oligomers (5 μM) at different time points. **(D)** WB analysis of total SynGAP levels in hippocampal neurons treated with Aβ oligomers (5 μM) plus rWnt-5a (300 ng/mL) at different time points. **(E)** Model of the effect of Aβ oligomers and the protective effect of rWnt-5a. The results are presented as the mean of *n* = 3 and 4 experiments and the statistical analysis was performed using one-way ANOVA, followed by Dunn's Multiple Comparison Test. ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.005.](fncel-09-00227-g003){#F3}

Previous studies indicate that Wnt-5a is able to prevent the Aβ synaptotoxicity triggered by the Aβ oligomers. Electrophysiological analysis of Schaffer collaterals-CA1 glutamatergic transmission in hippocampal slices demonstrated that Wnt-5a prevents the decrease in the amplitude of field excitatory postsynaptic potentials (~f~EPSPs). Moreover, Wnt-5a prevented the decrease of PSD-95 and synaptic loss in cultured hippocampal neurons ([@B8]). Additionally, the *in vivo* activation of Wnt signaling, with a mimetic peptide of Wnt-5a, rescues memory loss and improves synaptic dysfunction in APP/PS1-transgenic mice, a model the amyloid pathology of AD ([@B56]; [@B65]). Considering this evidence, we decided to evaluate the neuroprotective effects of Wnt-5a over SynGAP. The co-incubation of Wnt-5a with Aβ oligomers, reduced the number of apoptotic neurons at 120 min of treatment, time in which Aβ alone shows a slight increase in the apoptotic rate (Supplematary Figure [S1](#SM1){ref-type="supplementary-material"}). Hippocampal neurons treated with Aβ oligomers in the presence of the Wnt-5a ligand, showed a decrease in the SynGAP clusters (**Figure [3B](#F3){ref-type="fig"}**), very similar to the observed by the treatment with Wnt-5a alone (**Figures [2D,E](#F2){ref-type="fig"}**). At longer time of incubation, the SynGAP cluster number shows an increase close to control levels (**Figure [3B](#F3){ref-type="fig"}**), which is not observed in neurons treated with Aβ oligomers alone (**Figure [3A](#F3){ref-type="fig"}**). Interestingly, by WB analysis we observe that the total level of SynGAP is not altered when neurons were treated with Aβ oligomers in the presence of Wnt-5a (**Figure [3D](#F3){ref-type="fig"}**). This contrast with the effects observed in the cluster number of SynGAP when Wnt-5a is co-incubated with Aβ oligomers, in which we observe an inicial decrease. This suggest that the decrease observed at 5 min could be product of a translocation of SynGAP and not a loss in the protein level.

As shown in the model (**Figure [3E](#F3){ref-type="fig"}**), our results suggests that Aβ oligomers cause a disarrangement of SynGAP organization, which could be due to the PSD disassembling ([@B20], [@B21]). In our hypothetical model, Wnt-5a prevents the SynGAP loss induced by Aβ oligomers treatment by maintaining the integrity of the PSD and dendritic spines as previously has been reported ([@B8]; [@B64]). This allow that the initial decrease observed for SynGAP cluster density in the presence of Wnt-5a and Aβ oligomers (15 min) return to control conditions at longer times of incubations.

Discussion
==========

Wnt-5a is a synaptogenic factor, whose expression increases during development. It has been suggested that Wnt-5a plays a key role in synaptic function in the adult nervous system ([@B29]; [@B32]). Emerging *in vitro* and *in vivo* studies have implicated Wnt signaling in synaptic plasticity, regulating LTP ([@B9]), and episodic memory ([@B65]). Furthermore, activation of Wnt-5a signaling has shown to protect against Aβ-induced synaptic impairment ([@B8]; [@B64]; [@B65]). However, the molecular targets of their activity are just beginning to be elucidated.

Synaptic GTPase-Activating Protein is a prominent Ras/Rap GTPase-activating protein located in the PSD. It regulates the timing of spine formation and trafficking of glutamate receptors in cultured neurons ([@B53]). The role of SynGAP in plastic processes has been well established. SYNGAP1 knockout mice show deficits in NMDAR-dependent LTP ([@B36]) and have deficits in learning and memory ([@B14]).

In the present study, we evaluated the hypothesis that treatment with Wnt-5a modulates SynGAP function in hippocampal neurons, considering first, that SynGAP is a predicted target of a Wnt-5a-regulated microRNA, miR-101b, and second, that CaMKII activity is a major component in the signaling of both proteins. Our results show that endogenous SynGAP is down-regulated in HT-22 cells transfected with miR-101b mimic which validate the *in silico* prediction. In agreement with this observation and considering that Wnt-5a generates a significant decrease in the levels of miR-101b ([@B16]), the treatment with Wnt-5a generates an increases in the total levels of SynGAP in hippocampal neurons at 1 h of stimulation. The meaning of this regulation could be related to the increase in protein translation observed in synaptic plasticity process ([@B35]; [@B54]; [@B18]), however, additional experiments are required to confirm this hypothesis.

The GAP activity of SynGAP is increased by direct phosphorylation of serine residues by CaMKII ([@B50]). The treatment with Wnt-5a, increases the phosphorylation of S1123 residue of SynGAP, a major phosphorylation target of CaMKII. Additionally, we observed that the kinetics of this effect is similar to the activation of CaMKII induced by Wnt-5a. Both proteins increased their levels with a peak in 15 min and then return to basal levels. This finding is interesting because it suggests that the increase in intracellular calcium levels mediated by Wnt-5a might activate SynGAP. In the literature, is normally accepted that the calcium source that results in SynGAP activation is the influx mediated by NMDAR, posterior to LTP induction ([@B39]; [@B53]; [@B2]). In the Wnt/Ca^2+^ pathway, the Wnt-5a ligand activates PKC, CaMKII and calcineurin, by increasing the intracellular calcium concentration coming from internal stores ([@B40]; [@B38]; [@B47]), suggesting a mechanism independent of NMDAR activation. However, is possible that the Wnt/Ca^2+^ pathway activate SynGAP through NMDAR modulation. Recent reports show that Wnt-5a increases the GluN2B subunit of the NMDAR on the hippocampal neuronal cell surface ([@B47]). Additionally, Wnt-5a acutely and specifically upregulates synaptic NMDAR currents in rat hippocampal slices ([@B9]). Further studies are necessary to determine if the mechanism of activation of SynGAP mediated by Wnt-5a, is independent of NMDAR activation or could result from NMDAR modulation.

The functional consequence of SynGAP activation has been highly debated because RAS and RAP, their major targets at the synapse, have opposite effects in synaptic strength modulation. Active Ras increases insertion (exocytosis) of AMPARs at the synapse; whereas, active Rap increases their removal (endocytosis) from the synapse ([@B71]). Additionally, SynGAP has also been reported to have a promiscuous GTPase activity that directly or indirectly regulates the small G-proteins Rac1, and Rab5, which may in turn regulate the actin cytoskeleton and membrane trafficking involved in LTP-induced increases in spine size and AMPAR recruitment ([@B7]). Wnt-5a signaling induces a strengthening of synapses which is inconsistent with the Ras inhibition induced by SynGAP. However, a recent report shows that differential phosphorylation of SynGAP by CaMKII and CDK5 may alter the proportions of activated Ras and Rap in synapses with consequent effects on the cellular processes regulated by the two GTPases ([@B67]). Phosphorylation of SynGAP by CaMKII at S1123 accelerates the rate of inactivation of Rap more potently than the rate of inactivation of Ras; whereas, phosphorylation by CDK5, which occurs at S773 and S802, has the opposite effect ([@B67]). Another interesting mechanism of regulation of SynGAP mediated by CaMKII was recently described, in which their phosphorylation triggers a rapid dispersion of SynGAP clusters from synaptic spines, activating synaptic Ras and inducing LTP ([@B2]). We observe a fast and significative reduction of SynGAP cluster number after Wnt-5a treatment, without a reduction in SynGAP protein levels, which is consistent with a translocation of SynGAP from aggregates (presumably dendritic spines) to a diffuse pool in dendritic shaft. The timing of reduction in cluster number is similar to the peak of phosphorylation of SynGAP and CaMKII. The cluster number returns to basal levels more slowly than the dephosphorylation of SynGAP and CaMKII. This suggests that this post-transcriptional modification is necessary for cluster translocation. However, the re-insertion of the clusters in the PSD could implicate additional mechanisms.

In addition to its synaptic role, Wnt-5a is able to protect neurons against Aβ oligomers synaptotoxicity. Deregulation of the Wnt signaling has been suggested as an etiological cause for AD ([@B29]), which correspond to the most common type of dementia in people over 65 years old, in which death or malfunction of neurons causes changes in memory, behavior, and cognition ([@B60]). Synaptic pathology is an early event in AD, and soluble Aβ oligomers are principal responsible for the synaptic failure. Long before the occurrence of plaque deposition and neuronal death ([@B68]). Activation of Wnt-5a signaling rescues memory loss and improves synaptic dysfunction in both *in vivo* and *in vitro* models of AD ([@B8]; [@B64]; [@B56]; [@B65]). Considering the importance of SynGAP signaling in plastic and cognitive processes, it results surprising the absence of reports studying the role of SynGAP in AD mice models. For this reason, we evaluate the clustering of SynGAP in the presence of Aβ oligomers. The treatment with 5 μM of Aβ oligomers generates a fast and significant decrease in SynGAP level which becomes more pronounced in time. The initial decrease in SynGAP cluster number could be attributable to an increase in intracellular calcium levels, as has been reported previously for Aβ oligomers ([@B34]). However, the fact that the cluster number continues to decrease, as opposed to what is observed with Wnt-5a, suggests that the reduction is the result of synaptic toxicity. Interestingly, the co-application of Wnt-5a prevents this toxic effect. This probably explains why, when Aβ oligomers are co-applied with Wnt-5a we do not observe a decrease in SynGAP clusters. Moreover, it shows a similar effect to the one observed for Wnt-5a treatments. This observation is also similar to the previously reported effects of Wnt-5a in the clustering of PSD-95. Which drastically decreased in the presence of Aβ oligomers, while the co-incubation with Wnt-5a prevented such changes ([@B8]). The loss of SynGAP clusters in the presence of Aβ oligomers, could be due to the loss of PSD-95, considering that this scaffolding protein binds SynGAP through their PDZ (Postsynaptic Density Protein-95, *Drosophila* Disk Large Tumor Suppressor, and Zonula Occludens-1) domains. The fact that Wnt-5a prevents the loss of PSD-95 and dendritic spine structure in the presence of Aβ oligomers, helps to preserve the platform that allow the recovery of SynGAP clustering. Additional experiments are necessary to evaluate further mechanisms involved in the regulation of this phenomenon.

In the present work, we show for the first time the effect of Wnt-5a ligand over SynGAP function. Wnt-5a regulates the expression of SynGAP by a mechanism that could involve miRNA modulation. Additionally Wnt-5a regulates the phosphorylation levels (activity) and localization of SynGAP. Finally, we report that Aβ oligomers disturb the distribution of SynGAP and that Wnt-5a can protects against this synaptotoxic effect.
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